Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

First Patient Dosed in Immunotherapy Trial for Relapsed Refractory Ovarian Cancer

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Enrollment information for DRUG FACTORY Implants in Ovarian Cancer Trial is now up on the Clinical Trials website! 👏 Check here:, By Ovarcome

Avenge Bio on LinkedIn: Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian…

Avenge Bio secures FDA designation for mesothelioma therapy

BioCentury - Asif Ali to join Protagonist as CFO

Commercialization Highlights, Office of Technology Transfer, Office of Research

Lauren Jansen - Sr. Director of Process Development - Avenge Bio

avengebio (@AvengeBio) / X

Avenge Bio on LinkedIn: #asco23